- Home
- MRM vs BIVI Comparison
MRM vs BIVI Comparison
Compare MRM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- BIVI
- Stock Information
- Founded
- MRM 2000
- BIVI 2013
- Country
- MRM Japan
- BIVI United States
- Employees
- MRM N/A
- BIVI N/A
- Industry
- MRM Other Consumer Services
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- BIVI Health Care
- Exchange
- MRM Nasdaq
- BIVI Nasdaq
- Market Cap
- MRM 15.8M
- BIVI 14.2M
- IPO Year
- MRM 2020
- BIVI N/A
- Fundamental
- Price
- MRM $1.99
- BIVI $1.33
- Analyst Decision
- MRM
- BIVI
- Analyst Count
- MRM 0
- BIVI 0
- Target Price
- MRM N/A
- BIVI N/A
- AVG Volume (30 Days)
- MRM 377.0K
- BIVI 94.8K
- Earning Date
- MRM 05-22-2026
- BIVI 11-10-2025
- Dividend Yield
- MRM N/A
- BIVI N/A
- EPS Growth
- MRM N/A
- BIVI N/A
- EPS
- MRM 0.04
- BIVI N/A
- Revenue
- MRM $55,915,220.00
- BIVI N/A
- Revenue This Year
- MRM N/A
- BIVI N/A
- Revenue Next Year
- MRM N/A
- BIVI N/A
- P/E Ratio
- MRM $47.31
- BIVI N/A
- Revenue Growth
- MRM 12.79
- BIVI N/A
- 52 Week Low
- MRM $0.34
- BIVI $1.25
- 52 Week High
- MRM $4.45
- BIVI $31.50
- Technical
- Relative Strength Index (RSI)
- MRM 46.66
- BIVI 34.56
- Support Level
- MRM $1.98
- BIVI $1.25
- Resistance Level
- MRM $2.14
- BIVI $1.48
- Average True Range (ATR)
- MRM 0.09
- BIVI 0.11
- MACD
- MRM -0.01
- BIVI -0.01
- Stochastic Oscillator
- MRM 47.83
- BIVI 24.40
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.